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Translational Relevance 
 
Antigen-specific cancer vaccines are designed to induce durable tumor-reactive 
immune responses to effectively control cancer growth. This study presents clear 
evidence for the immunogenicity of the NY-ESO-1 protein combined with CpG 
7909 to prime antigen-specific naïve B- and T-cells, and to induce NY-ESO-1 
specific, tumor-reactive CD8+ T-cells in patients with metastatic prostate cancers. 
NY-ESO-1-specific humoral (100%) and cellular (69%) immune responses were 
elicited in vaccinated patients independent of any detectable NY-ESO-1 expression 
in the autologous tumor. Based on the capacity of the vaccine to effectively prime 
specific immune responses in patients with advanced cancer, we further consider the 
use of this vaccine in adjuvant and preventive treatment settings.  
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Abstract 
Purpose: NY-ESO-1, one of the most immunogenic tumor antigens, is expressed in 
15-25% of metastatic prostate cancers. The immunological and clinical effects of 
vaccination with recombinant NY-ESO-1 protein combined with CpG as adjuvant 
were evaluated. 
 
Experimental Design: In a phase I clinical study, patients with advanced prostate 
cancer were vaccinated with recombinant NY-ESO-1 protein (100 µg) mixed with 
CpG 7909 (2,5 mg) every 3 weeks intradermally for 4 doses. Objectives of the study 
were the safety of the vaccine and changes of specific humoral and cellular 
immunological responses to NY-ESO-1 in relation to detectable NY-ESO-1 
expression in the individual tumor. 
 
Results: All 12 baseline sero-negative patients developed high-titer NY-ESO-1 
antibody responses. B-cell epitope mapping identified NY-ESO-1 p91-110 to be 
recognized most frequently by vaccine-induced antibodies. Two patients developed 
significant antibody titers against the adjuvant CpG. NY-ESO-1-specific CD4+ 
and/or CD8+ T cell responses were induced in 9 patients (69%). Five of these 9 
patients did not express NY-ESO-1 in the autologous tumor. Post-vaccine CD8+ T-
cell clones recognized and lyzed HLA-matched tumor cell lines in an antigen-
specific manner. 
 
Conclusion: Our data provide clear evidence for the capacity of NY-ESO-1 
protein/CpG vaccine to induce integrated antigen-specific immune responses in vivo 
and to efficiently prime CD8+ T-cell responses in NY-ESO-1 antigen-negative 
patients. Our results may also support further clinical vaccination protocols with 
NY-ESO-1 protein not only focused on the treatment of existing cancer, but also to 
prevent further development of NY-ESO-1 positive cancers in vivo. 
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Introduction 
NY-ESO-1 is the most immunogenic cancer-testis tumor antigen known to date. It is 
widely expressed in cancers including breast, bladder, prostate, melanoma, NSCLC, 
sarcoma and ovarian cancers where expression ranges stage-dependent from 20 to 
80% of tumors. (1-4). The antigen often elicits spontaneous humoral und cellular 
immune responses against multiple MHC class I and II restricted NY-ESO-1 
peptides in a proportion of patients with NY-ESO-1 positive tumors (5-10). Several 
clinical vaccine trials with different NY-ESO-1 formulations have shown that these 
vaccines are generally well tolerated and that cellular and humoral immune 
responses can be elicited in cancer patients (11-13). Although the initial trials were 
designed to primarily assess the safety and immunogenicity of the vaccine, a clinical 
benefit with extended time-to-progression intervals and regression of single disease 
parameters was observed in some patients who had developed detectable immune 
responses to the vaccine (14-15). Because NY-ESO-1 is presented on the surface of 
tumor cells only in the context of MHC molecules, it is important that the antigen-
specific vaccine induces tumor-reactive NY-ESO-1 specific CD4/CD8 T-cells. 
Previous studies with recombinant NY-ESO-1 protein have shown that humoral and 
cellular immune responses were more efficiently induced when the antigenic protein 
was combined with a potent adjuvant as compared with protein alone (16-18). Of 
these adjuvants available, synthetic CpG oligodeoxynucleotides that bind to TLR9 
expressed in B-cells and plasmacytoid dendritic cells, are likely to elicit 
proinflammatory cytokines, stimulate Th1-type immune responses and directly 
activate human B-cell proliferation and dendritic cell maturation resulting in an 
enhanced antigen-specific T-cell response (19-25). There is evolving evidence that 
NY-ESO-1 expression in the tumor changes from negative to positive during the 
progression of disease (26). In ovarian cancers, patients with stage 1 and 2 disease 
showed 14 % expression of NY-ESO-1 while patients with stage 3 and 4 disease 
showed an increase to 46% (27). In prostate cancer, which is known to be a 
relatively slow progressing disease, expression ranges stage dependant from 5-30% 
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(28-29). Therefore immunotherapeutic interventions at an early stage of disease in 
an adjuvant setting may improve immunosurveillance and possibly alter the clinical 
development. Patients in this study were vaccinated regardless of detectable NY-
ESO-1 tumor antigen expression. Any vaccine-induced antigen-specific immune 
response in antigen-negative patients would underline the potential of the vaccine 
not only to induce antibodies and CD4+ T-cell responses but also efficiently prime 
naïve CD8+ T-cells. In the present study, we have assessed the immune responses 
elicited by vaccination with recombinant NY-ESO-1 protein mixed with CpG 7909. 
We show that prostate cancer patients receiving this vaccine develop integrated 
antibody and CD4+/CD8+ T-cell responses to NY-ESO-1. A significant proportion 
of them did not express NY-ESO-1 in the tumor. These findings support the 
potential of recombinant NY-ESO-1 protein vaccine when combined with CpG to 
induce protective antibody and T-cell mediated immunity.  
 
 
Material and Methods 
Investigational Agents 
Full-length human recombinant NY-ESO-1 protein was expressed in E. coli and 
purified using multi-step chromatography.  The protein was formulated in 4 M urea 
containing 50 mM glycine and was provided by the Ludwig Institute for Cancer 
Research Ltd. CpG 7909, a single stranded 24 base phosphorothioate 
oligodeoxynucleotide (ODN) with the base sequence 5´TCG TCG TTT TGT CGT 
TTT GTC GTT 3´, was synthesized and provided by Coley Pharmaceutical Group, 
Wellesley, MA, USA. Synthetic NY-ESO-1 peptides p157-165 and p157-170 were 
provided by the Ludwig Institute for Cancer Research Ltd. 
All syntheses, productions, formulations and packaging of the investigational agents 
were performed in accordance with applicable current Good Manufacturing 
Practices and met the applicability criteria for use in humans. 
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Study Design 
This study was an open-label fixed-dose phase I study of immunization with 
recombinant NY-ESO-1 protein combined with CpG 7909 as an adjuvant in patients 
with high-risk stage D1 or advanced prostate cancer. Patients were included after 
giving written informed consent and received i.d. injections of 100 µg NY-ESO-1 
protein mixed together with 2,5 mg CpG as an adjuvant every 3 weeks for 4 doses 
according to study protocol LUD03.024 which was approved by the Ludwig 
Institute for Cancer Research as well as by the medical and ethical committees of 
Hessen/Germany. Expression of NY-ESO-1 or LAGE-1 in autologous tumor 
samples was assessed by RT-PCR and/or immunohistochemistry retrospectively. 
For DTH testing, HLA-A2 and/or HLA-DP4 positive patients received intradermal 
injections of synthetic HLA-A2 and/or HLA-DP4 restricted NY-ESO-1 peptides 
p157-165 and/or p157-170, respectively, at baseline and on weeks 7, 13, 22 and 28 
at a dose of 10µg peptide. DTH was assessed 48 hrs after each peptide injection. 
Blood samples were collected at baseline, prior to the second, third and fourth 
injection and three weeks after the fourth injection for clinical hematology, 
biochemistry, PSA levels and immune response assessments. Patients who 
demonstrated stable disease, minor, partial or complete response on week 13 were 
allowed to continue vaccinations until disease progression. In patients with mixed 
response, single progressive lesions could be resected and vaccination could be 
continued.  
 
Serological responses 
NY-ESO-1 specific antibodies (Abs) were measured in the serum by standard 
ELISA assays on the day of each vaccination and 3 weeks after the last vaccination 
as previously described (26). Briefly, sera were added to 96-well plates (Nunc 
Maxisorb) coated with 2µg/ml (50µl/well) antigen o/n at 4°C and blocked with 2 % 
BSA/PBS. After incubation, plates were washed with PBS and specific antibodies 
were detected with alkaline phosphatase-conjuncted anti-human IgG (Sigma 
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A9544). Following addition of pNPP (p-Nitrophenyl-phosphate) substrate and 3N 
NaOH stopping solution, absorbance was measured at 405 nm using an Anthos 
Laptec Instruments fluorescence reader.  Sera were assessed over a range of 
dilutions from 1:100 to 1:400000. Vaccine-induced Abs were mapped with a panel 
of overlapping 20mer peptides (25µg/ml) spanning the whole protein sequence by 
ELISA. Immunoglobulin subclasses G1 and G3 were determined by Western blot 
analysis as described (26) using secondary antibody mouse anti-human IgG1/IgG3 
at a dilution of 1:1000 (Zymed). In addition, sera were measured for serological 
responses against the CpG ODN adjuvant in standard ELISA at a coating 
concentration of 25µg/ml CpG 7909.  
 
NY-ESO-1 specific T cells 
For testing in enzyme-linked immunospot (ELISPOT) and cytotoxicity assays, 
purified CD8+ and CD4+ T-cells were presensitized with adenoviral NY-ESO-1 
(Ad2/ESO) -infected or NY-ESO-1 peptide pulsed irradiated autologous peripheral 
blood mononuclear cells (PBMC) depleted of CD4 and CD8 T-cells as described 
(30). Ad2/ESO was prepared by Dr. S.Yla-Herttuala (A.I. Virtanen Institute, 
University of Kuopio, Finland) for the Cancer Vaccine Collaborative. Presensitized 
CD4+ and CD8+ effector cells were tested on day 10-14 in γ-IFN ELISPOT assays 
for specific NY-ESO-1 reactivity using peptide-pulsed autologous antigen-
presenting cells (EBV-transformed B-cells and dendritic cells) as target cells. A 
positive response was considered if the number of spots in the peptide-exposed well 
was two-fold or more higher than the number of spots in the unstimulated well, and 
if there was a minimum of ten (after subtraction of background spots) peptide-
specific spots/25.000 T-cells or less if T-cell clones were used. For functional T-cell 
testing, cytotoxicity against NY-ESO-1 peptide-pulsed T2 cells and NY-ESO-1 
expressing tumor cell lines was determined in 51chromium release assays as 
described (31). In addition, tetramer analyses were performed in some patients using 
HLA PE-conjugated multimeric HLA-A2 and -Cw3 peptide complexes containing 
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NY-ESO-1 p157-165 and p96-104 synthesized at the Ludwig Institute of Cancer 
Research, Epalinges, Switzerland and used as described (15, 30). HLA-A2/HIVpol 
p476-484 and HLA-Cw3/ESOp92-100 tetramers were used as negative controls.  
 
 
Results 
Patients 
Fifteen patients were enrolled in this trial, 3 of them were treated at 
Universitätsspital Zürich, Switzerland, and 12 patients were treated at Krankenhaus 
Nordwest, Frankfurt, Germany. Eleven patients had metastatic disease, four patients 
had high-risk stage D1 prostate cancer. All patients had advanced disease and 
thirteen patients had received previous hormonal and/or chemotherapeutic 
treatment. Two patients had NY-ESO-1 expressing tumors, eight were NY-ESO-1 
negative, and in five patients NY-ESO-1 expression was not assessed. One patient 
(F-10) had NY-ESO-1 specific antibodies detectable at baseline. This patient had 
advanced disease including visceral and bone metastases. Thirteen patients 
completed at least 4 vaccinations and were therefore considered evaluable for 
immunological and clinical response. Two patients withdrew early from the study 
due to study drug related toxicity (ZH-3) and patients decision (F-2). Patient F-3 and 
F-6 continued vaccinations after 2 cycles since clinical benefit was observed and 
received the vaccine on the basis of compassionate single-patient protocols (SPP) 
for 15 and 20 additional injections according to the protocol, respectively. All 
patients received concomitant hormone ablative treatment. Summary of patient 
characteristics and clinical response are presented in Table 1.  
 
Toxicity 
All patients were evaluable for toxicity. WHO grade 4 toxicities were not observed, 
grade 3 toxicity (hypotension) occurred in one patient (ZH-3). All patients 
developed local erythema and pruritus at the site of vaccination lasting 5-7 days. 
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Patient F-8 developed a systemic hypersensitivity reaction (grade 2) with 
generalized rash. In patient ZH-3 hypotension (grade 3), swelling, blister formation 
and central necrosis developed at the site of vaccination (grade 2) after the first 
injection. Hypotension became symptomatic two days after the vaccination and was 
considered possibly related to the vaccination. Due to the episode of hypotension 
and the strong inflammatory response following vaccination, the patient was 
withdrawn from the study. 
 
DTH reactions  
DTH testing was performed with 10µg of NY-ESO-1 p157-165 and NY-ESO-1 
p157-170 peptide in HLA-A2+ and HLA-DP4+ patients, respectively. No DTH 
reactions to these peptides were observed. Patient F-10 was HLA-A2 and DP4 
negative and was therefore not tested for DTH reactions. 
 
Serological responses after vaccination with rNY-ESO-1 protein and CpG. 
Following injections of 100 µg rNY-ESO-1 protein together with 2,5 mg CpG 
intradermally every three weeks for 4 doses, one patient (F-10) showed NY-ESO-1 
antibodies at baseline that increased from 6.400 at week 1 to a maximum of 51.000 
(reciprocal titer) during vaccination. Patient ZH-3, who withdrew early, was only 
tested at baseline and at week 4 of vaccination. He remained sero-negative after one 
single vaccination. All other patients were sero-negative at baseline and developed 
significant serological responses against NY-ESO-1 during the course of 
vaccination. Specific IgG responses to NY-ESO-1 became generally detectable after 
the second injection between week 4 and 7 and titers further increased without 
generally reaching a plateau at a specific time point. Anti NY-ESO-1 IgG titers were 
variable among patients and did not correlate with the number of vaccinations. In 
addition, we analyzed serological responses against the adjuvant CpG 7909. Patients 
F-3 and F-8 developed vaccine-induced antibody responses against CpG with titers 
up to 1:25000 and 1:6400, respectively. Patient ZH-2 reacted with the adjuvant only 
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at one time point at study week 22 (Figure 1a). Maximum NY-ESO-1 Ab titers had 
reached 1:200000 after the first vaccine cycle in 2 patients, the other patients mostly 
developed maximum high titer Abs during the second cycle of vaccination. In some 
patients, persistence of vaccine-induced Abs was analyzed in follow up sera and 
remained detectable without further vaccination for up to 2 years after the last 
vaccination (Table 2). Vaccine induced NY-ESO-1 antibodies were of subtype IgG1 
and IgG3 in all patients with the exception of patient F-10 who had preexisting IgG1 
antibodies and who did not develop IgG3 antibodies. The IgG subtypes were 
compared to those found in patients with spontaneous NY-ESO-1 antibodies and in 
patients who seroconverted during vaccination with recombinant vaccina/folwpox 
NY-ESO-1 constructs (rV/rF-NY-ESO-1) in our previous trials. In both groups the 
dominant subtype was IgG1 only (Figure 1b). Epitope mapping of vaccine-induced 
antibodies with a panel of overlapping linear NY-ESO-1 20mer peptides showed 
recognition of B-cell epitopes located in the N-terminal part of the protein between 
p1-110. Within these regions, linear synthetic peptides p11-30, p51-70 and p91-110 
were recognized by all vaccine-induced antibodies and were the first epitopes to be 
recognized during antibody development. Among those, antibodies against p91-110 
often showed the strongest reaction in ELISA. No reactivity was found against 
epitopes located between region p120-180 with the exception of the C-terminal 
epitope p161-180 recognized by the serum of patient F-10. This B-cell epitope was 
so far more frequently found as the target epitope in patients with spontaneous NY-
ESO-1 antibodies. In contrast to spontaneous Ab responses or responses induced by 
vaccination with recombinant rV/rF- NY-ESO-1 or CHP-NY-ESO-1, sera of 
patients in this study also reacted with peptide p101-120 (Figure 1c). This epitope 
was shown to be serologically recognized in the present study for the first time. We 
did not observed B-cell reactivity with peptide p81-100 in both groups. This is 
interesting as it is within the hotspot mid domain of major known T-cell recognition 
on the NY-ESO-1 protein. 
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NY-ESO-1 specific CD4+ T cell responses 
Before vaccination none of the patients had detectable CD4+ T cell responses 
against NY-ESO-1. After vaccination CD4+ T cell responses against different NY-
ESO-1 epitopes were induced in 9 patients. The majority of CD4+ T-cells 
recognized sequences located in the three immunodominant distinct regions of the 
protein, corresponding to peptides p81-100, p119-143 and p151-180. Minor 
reactivity was found against some other peptides. Vaccine-induced CD4 epitopes 
are presented in Figure 2 and CD4 ELISPOT data of all patients are shown in 
Supplemental Table S1.  
 
NY-ESO-1 specific CD8+ T cell responses  
At baseline, none of the patients had detectable CD8+ T cell responses against NY-
ESO-1. During vaccination, detectable CD8+ T cell responses were induced in 6 
patients. The epitopes recognized by CD8+ T-cells included p81-100, p91-110, 
p119-143 and p157-165, consistent with previous findings in patients with 
spontaneous responses as well as in patients immunized with other full-length NY-
ESO-1 vaccines. Vaccine-induced CD8 epitopes are presented in Figure 2 and CD8 
ELISPOT data of all patients are shown in Supplementary Table S1.  
Two non HLA-A2+ patients (F-7 and F-10) developed CD8+ T cell responses 
against NY-ESO-1 p91-110 at week 10 of immunization. Patient F-9, who was 
HLA-A2 positive, showed a CD8+ T-cell response against NY-ESO-1 p157-165 at 
week 10 of immunization that was detectable also ex vivo with a frequency of 120 / 
106 CD8+ T cells. Most T-cell responses developed early during the first cycle of 
immunization (Table 2). In patient F-3 and F-6, CD4/CD8 T-cells became 
detectable later during the second cycle. To evaluate the functional activity of 
vaccine-induced NY-ESO-1 specific T cells, we established CD8+ T cell clones 
from bulk cultures of patients F-7 and F-9 by limiting dilution using peptide-pulsed 
APC for stimulation. NY-ESO-1 p157-165 specific T-cell clones of patient F-9 
showed reactivity against the NY-ESO-1 expressing HLA-A2+ tumor cell lines SK-
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MEL-37 and NW-MEL-1045, CD8 T-cell clones from patient F-7 recognized NY-
ESO-1 p91-110, and reacted with the NY-ESO-1 expressing tumor cell line MZ-
MEL-7 as assessed in 51chromium release assay (Figure 3A and B). CD8 T-cell 
clone 21 of patient F-7 was further analyzed by using overlapping 9-mer peptides 
covering the region p91-110 of the NY-ESO-1 protein. The exact minimal NY-
ESO-1 peptide p96-104 was identified as the target epitope recognized by this T-cell 
clone. NY-ESO-1 epitope and HLA specificity of the T-cell clone was confirmed by 
HLA-Cw3/p96-104 tetramer staining, while the control tetramer HLA-Cw3/p92-100 
did not bind to the T-cell clone (Figure 3B right).  
In order to determine the stability and longevity of vaccine-induced NY-ESO-1 
specific CD8 and CD4 T-cell responses, PBMCs were obtained in some patients 
after completion of vaccination. NY-ESO-1 specific vaccine-induced CD4+ T-cells 
in patient F-3, F-9 and ZH-2 were still detectable after 24, 3 and 2 months, 
respectively. Vaccine-induced CD8+ T-cells of patient F-3 specific for NY-ESO-1 
p81-100 were detected during vaccination outside the standard protocol and during 
2 years following completion of vaccination. 
 
Clinical tumor response 
Of fifteen patients, 13 completed 4 vaccinations and were evaluable for clinical and 
immunological response. Most patients had advanced disease already at primary 
diagnosis. Eleven of the evaluable patients had stage IV disease at study entry. No 
early or rapid tumor progression and no partial or complete responses were seen. 
After four vaccinations, eight patients showed stable disease (F-1, F-3, F-4, F-5, F-
6, F-10, F-12, ZH-2), three had progressive disease (F-7, F-9, ZH-1), and two 
patients remained free of detectable disease (F-8 and F-11). Clinical responses were 
determined by radiological staging and course of PSA values. All patients had 
concomitant antihormonal treatment. Patients F-1 and F-5 started first line 
antihormonal therapy at study entry. Therefore, the clinical development in these 
two patients may also be related to this treatment. Time to progression was 
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considered from the beginning of therapy to the date of disease progression. The 
median time to progression was 4,75 months, ranging from 0 to 16 months in all 
patients. Three patients (F-3, F-6, ZH-2) had extended time-to-progression intervals 
≥ 8 months during or following vaccination. Patient F-3 experienced disease 
stabilization. Known bone metastases remained unchanged while PSA values 
decreased from 31,5 µg/l at baseline to 12,8  µg/l at week 10 and 11,8 µg/l at week 
25. Vaccination was therefore continued in a compassionate setting. Time until 
progression of disease was 8 months. Since then, the patient had received alternating 
sequences of antihormonal- and cytotoxic therapy. This patient continues to show a 
favorable clinical development since study entry and is alive with disease for more 
than 15 years since initial diagnosis. Patient F-6 achieved radiologically confirmed 
disease stabilization underlined by declining PSA values from 20,9 µg/l at study 
entry to 12,7 µg/l at week 16. The patient received continued vaccination according 
to the protocol for a total of 11 months as a compassionate treatment until disease 
progression. Considering a median time to progression of 6,5 months in patients 
with advanced prostate cancer under conventional chemotherapy, the clinical 
courses of these patients are considered outstanding. 
 
Immune response and clinical tumor response 
Time to progression in patients who developed specific CD4 and CD8 T cell 
responses against NY-ESO-1 peptides (F-3, F-4, F-7, F-9, F-10, F-12) was 15.8, 4, 
0, 0, 4 and 4.4 months, respectively. There was no correlation between detectable 
immune response and clinical stage or development of disease. Patients F-2 and F-
10 had NY-ESO-1 expressing tumors. Patient F-2 completed only two vaccinations 
and was therefore not evaluable for immunological and clinical response. Patient F-
10 had NY-ESO-1 serum antibodies at baseline. The antibody titer increased during 
vaccination and NY-ESO-1 specific CD8 and CD4 T cells were detected by 
ELISPOT analysis after 4 vaccinations. Time to progression in this patient 
diagnosed with liver, bone and lymph node metastases was 4 months.  
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Discussion 
Among the broad range of NY-ESO-1 specific immunotherapies evaluated during 
the past years, recombinant NY-ESO-1 protein vaccines are expected to induce a 
broader spectrum of epitope-specific T-cell immune response as compared with 
single or short peptide-based vaccine formulations that are limited in their use by the 
respective HLA restriction. In addition, NY-ESO-1 antibody responses were 
induced in almost all patients receiving NY-ESO-1 protein vaccination (16, 32-34). 
However, the biological role of NY-ESO-1 antibody in the development of the 
disease is not yet understood. Spontaneous NY-ESO-1 antibodies were found more 
frequently in patients with advanced tumor stages, suggesting that the duration of 
antigen exposure and antigen load play a major role for the induction of humoral 
immune responses, in particular since the antigen is not expressed on the surface of 
tumor cells (26). Therefore vaccination with NY-ESO-1 protein along with the 
adjuvant activity of CpG may overcome the insufficient immunogenicity of early 
stage tumors for inducing antibody responses. As detailed analysis of spontaneous 
and vaccine induced immune responses have shown, the development of NY-ESO-1 
antibody is often associated with detectable NY-ESO-1 specific T-cell responses 
(8). This study presents the immunological and clinical results after vaccination with 
recombinant NY-ESO-1 protein combined with CpG 7909 in patients with high-risk 
stage D1 or advanced prostate cancer. The primary objective of the study was to 
evaluate the safety of the vaccine. Secondarily, the study evaluated the specific 
immunological response to NY-ESO-1 protein regardless of NY-ESO-1 expression 
in the autologous tumor. The vaccine was safe and well tolerated. One patient 
experienced WHO grade 3 toxicity (hypotension) possibly related to the vaccine. No 
other grade 3 or 4 toxicities were observed. DTH responses in all patients were 
negative and can probably be explained by the low dose of 10 µg of peptide injected 
for DTH testing. In previous studies, DTH tests were performed with 30 or 100 µg 
of peptide and DTH reactions were observed even if the peptide was used alone, 
without further adjuvant (35). Except for one patient who received only one single 
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vaccination, all baseline sero-negative patients developed high-titer NY-ESO-1 
specific IgG antibody responses still detectable in some patients at a 1/200.000 
dilution. The frequency of antibody induction was similar to other NY-ESO-1 
protein vaccination studies using either different delivery forms of recombinant 
protein such as cholesterol-hydrophobized-pullulan (CHP-NY-ESO-1) (33), or 
protein alone combined with different adjuvants e.g. ISCOMATRIX, that forms 
lipid/saponin-based cage-like structures (16) or CpG (34). Out of these adjuvants, 
CpG 7909 that potently stimulates B-lymphocytes was likely to be responsible for 
the high antibody titers found in our study. Maximum vaccine induced antibody 
titers differed among patients but were generally high. Vaccine-induced antibodies 
were of IgG1 and IgG3 subtype. In contrast, IgG1 was the dominant subtype in 
patients after vaccination with rV/rF-NY-ESO-1 and CHP-NY-ESO-1, or in patients 
with spontaneous humoral immunity (36). Both, IgG1 and IgG3 subclass antibodies 
usually represent the humoral response to protein antigens and interact with the 
activating Fcγ-receptor IIa (CD32a) expressed on monocytes, B-cells and 
monocycte-derived dendritic cells. The antigenic epitopes recognized by antibodies 
in NY-ESO-1 protein vaccinated patients were similar to those recognized in cancer 
patients with spontaneous or CHP-NY-ESO-1 and rV/rF-NY-ESO-1 induced 
humoral immunity with the additional recognition of epitope p101-120 that was 
identified here for the first time in the majority of patients. Antibody responses 
against epitope p101-120 may be related to differences in protein formulation, the 
cDNA cloning systems or to the CpG and require further investigations. With 
respect to the immunodominance and hierarchies of recognition among NY-ESO-1 
epitopes, it is remarkable that within the same hotspot mid-domain (p81-110) of T-
cell reactivity, there is an analogy between B-cell and T-cell recognition of NY-
ESO-1 epitope p91-110 while no B-cell reactivity with p81-100 was observed. 
Therefore it would be important to analyze if the antibody itself can recognize tumor 
cells directly that present this epitope on the cell surface in complex with HLA, even 
though NY-ESO-1 is an intracellular tumor antigen.  
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Of note, two patients developed antibodies against the CpG oligodeoxynucleotides 
used as adjuvant. The development of an immune response against the adjuvant 
itself has been previously described, e.g. against keyhole limpet hemocyanine 
(KLH) and anti-CpG-DNA antibodies have been previously described in ODN-
injected mice (37). However, this is the first time that anti-CpG antibodies have 
been described against short unmethylated CpG dinucleotide sequences in humans. 
This finding was confirmed by re-analysis of our previous study LUD02.007, where 
three out of eight patients vaccinated with NY-ESO-1 peptide combined with CpG 
7909 also developed CpG-directed antibodies (supp. Figure1). The CpG-directed 
antibodies do not seem to have a neutralizing effect since both patients developed 
high antibody titers against NY-ESO-1 protein and, in addition, generated NY-ESO-
1 specific T-cell responses in the presence of CpG-directed antibodies.  
In the present study most patients who developed vaccine-induced antibodies 
showed integrated CD4+ (9/13) and CD8+ (6/13) T-cell responses simultaneously. 
The frequency of T-cell response was in accordance with the findings of Valmori 
et.al. (34) who reported CD4+ T-cell responses in 17 of 18 patients and CD8+ T-cell 
responses in 9 of 18 patients after vaccination with the same antigenic protein 
combined with CpG and Montanide. In both studies patients were treated regardless 
of demonstrable expression of NY-ESO-1 in the autologous tumor. Focusing on 
tumor-antigen negative patients only, CD8+ T-cell responses were induced in 4 of 7 
patients in our study and in 6 of 8 patients in the study by Valomori et.al. Therefore, 
the impact of Montanide for the immunogenicity of NY-ESO-1 protein/CpG 
vaccine formulation seems to be less significant as demonstrated in several peptide-
based vaccine studies in which Montanide as an adjuvant was found to enhance 
antigen specific T-cell responses, documented by ex vivo detectable T-cell 
activation (38). CD8 T-cell responses in most cases occurred concurrently with 
CD4, and both concomitantly with high titer NY-ESO-1 specific antibodies, 
suggesting that specific antibodies may play an important role in priming of NY-
ESO-1 specific CD8+ T-cells by forming immune complexes with the vaccine 
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protein that allow a better delivery of the protein to antigen presenting cells (39). 
Vaccine-induced CD4+ and CD8+ T-cell responses in our study were 
predominantly directed against the known immunodominant NY-ESO-1 regions 
p81-110, p119-143 and p157-170 that have been described previously (14, 34, 40). 
In addition, we could demonstrate functional activity of vaccine induced CD8+ T-
cell clones, which were able to recognize naturally processed NY-ESO-1 epitopes 
presented by tumor cells. Patient F-9 even exhibited an ex vivo detectable T-cell 
response against NY-ESO-1 p157-165. Direct ex vivo antigen-specific T-cells are 
rarely detected, but were found in several previously published studies either with 
NY-ESO-1 p157-165 peptide or Melan-A ELAGIGILTV analog peptide when the 
vaccines were combined with Montanide and CpG (15, 41, 42). These studies 
indicate the important role of CpG as an adjuvant in peptide-based and recombinant 
protein vaccines. Furthermore, if coadministrated with the NY-ESO-1 protein, CpG 
ODNs quite possibly initiate DC activation and thus may enhance the development 
of specific CD8+ T-cell responses. Interestingly, 3 patients developed NY-ESO-1 
specific IgG antibodies without detectable NY-ESO-1 specific CD4 T-cells and all 
CD4 responder developed antibody responses prior to the CD4 response. This 
suggests, that CpG may be able to bypass the antigen-specific T-helper cell response 
required for the subclass switch from IgM to IgG. 
In summary, our study demonstrated that NY-ESO-1 protein vaccination at a dose 
of 100 µg combined with CpG ODNs is highly immunogenic and able to elicit 
primary antigen-specific humoral, CD4+ and CD8+ T- cell immune responses in 
patients with or without NY-ESO-1 expressing tumors. This vaccine approach may 
open the possibility for the design of further vaccinations in an adjuvant setting 
including both, target-antigen specific and antibody-based immunotherapies to 
protect patients with high-risk tumor stages from tumor expansion.   
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Tables  
 
Table 1: Patient characteristics and clinical response  
 
Table 2: Summary of vaccine-induced immune responses 
 
Figure legends 
Figure 1: Serological responses to the vaccine 
A: NY-ESO-1 antibody responses (blue line) were assessed in ELISA at baseline and 
at indicated study weeks during vaccination. OD values at 405nm at a serum dilution 
of 1:400 were shown. Anti-CpG antibody responses are shown by the green line. As a 
control sera were tested against the unrelated MAGE-3 protein (pink line).  
B: Western blot analysis for the determination of antigen specific IgG subclass 
antibodies in patients after NY-ESO-1 protein vaccination. Data from patients with 
spontaneous NY-ESO-1 or rV/rF-NY-ESO-1 induced antibodies were shown in the 
lower line. Patient’s sera were added at a dilution of 1:250. 
C: Comparative analysis of B-cell epitopes recognized by NY-ESO-1 protein 
vaccine-induced antibodies (left graph) and by rV/rF-NY-ESO-1 vaccine-induced or 
spontaneous antibodies (right graph). Linear 20mer overlapping peptides spanning 
the NY-ESO-1 protein sequence were determined using patients sera at a serum 
dilution of 1:400 and displayed as a comparison of single epitopes with regard to the 
total sum of OD values recognized by all patients after subtraction of background 
values.  
 
Figure 2: NY-ESO-1 epitopes recognized by post-vaccine T-cells  
CD4+ and CD8+ T-cells were prestimulated with Ad2/ESO infected or NY-ESO-1 
peptide loaded PMBCs and tested in γ-IFN ELISPOT on peptide loaded autologous 
or allogeneic APC. Before vaccination, antigen-specific T-cells were not detected.  
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Figure 3: NY-ESO-1 protein vaccination elicits antigen-specific and tumor-
reactive CD8+ T-cells  
A: Specific cytotoxicity of post-vaccine T-cell clone 8 from patient F-9 against 
HLA-A2/NY-ESO-1 expressing tumor cell lines SK-MEL-37 and NW-MEL-1045. 
Right: NY-ESO-1 p157-165 specificity of T-cell clone 8 was confirmed by flow 
cytometry using p157-165/HLA-A2 tetramer. As negative control, T-cells were 
stained with HLA-A2/HIV multimers (ILKEPVHGV).  
B: Specific cytotoxicity of CD8 T-cell clone 21 from patient F-7. NY-ESO-1 p96 -
104 (FATPMEAEL) was recognized on peptide pulsed autologous EBV-B-cells. 
Cross-reactivity against naturally processed NY-ESO-1 on tumor cell line NW-
MEL-9 is shown. NY-ESO-1 negative tumor cell line NW-MEL-12, autologous 
EBV-B-cells and K562 were not recognized. Right: Epitope specificity was 
confirmed by tetramer staining using Cw0304/p96-104 multimers.  
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Patient Initial stage Stage at Metastases Tumor NY-ESO-1 Biopsy No. of Best Time to Overall Total Toxicity
at diagnosis study entry expression (IHC) site Vacc. ResponseProgression SurvivalSurvival (grade) ¶
F-1 IV IV B, LN - Prostate    8 SD 5.9 8.3 10 L(2), S(1)
F-2 II IV NED + Bladder       2  n.e. n.e. 10.8 168 L(2), S(2)
F-3 II IV B - Prostate    15 SD 12 64,3 +     180 + L(2), S(1)
F-4 unknown IV B -  LN             5 SD 4 34.3 96 L(2), S(1)
F-5 IV IV B, LN n.a. 8 SD 6.2 6.3 9 L(2), S(1)
F-6 unknown IV B n.a. 20 SD 12.4 63.4 72 L(2), S(1)
F-7 II III NED - Prostate     4 PD 2.5 14.5 108 L(2), S(2)
F-8 III-IV IV NED n.a. 7 NED 5.1 33.8 96     L(2), S(2)  §
F-9 III IV B n.a. 4 PD 3 18.2 108 L(2), S(2)
F-10 unknown IV Li, LN, B + Prostate   6 SD 4 8 60 L(2), S(2)
F-11 III III NED - Prostate 6 NED n.e.† 7.7 120 L(2), S(2)
F-12 IV IV LI, LN - Prostate   6 SD 4.4 11.1 12 L(2), S(2)
ZH-1 III IV LN - Prostate   4 PD 3 3.5 61 L(2), S(2)
ZH-2 IV IV B, LN - Prostate  8 SD 10.5 54 132 L(2), S(2)
ZH-3 III IV B - Prostate  1  n.e. n.e. 25 36     L(2), S(3)  §
¶ L:  local injection reaction including reddening, swelling, pain              
   S:  related systemic toxicity including fever, chills, flu like-syndrome, headache, myalgia, athralgia, sweating, tachycardia, nausea, diarrhoea 
   §:  reaction leading to study termination: F-8 hypersensitivity CTC 2; ZH-3 hpotension CTC 3
   †:  patient started new treatment prior to progression
   LI, liver; LN, lymph node; B, bone; n.e., not evaluable; n.a., not applicable NED, no evidene of disease; Vacc., vaccinations, all time dates in months.
   Time to progression, Overall survival, Total survival: in months;  IHC: Immunohistochemistry
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    L(2), S(2)  §
    L(2), S(3)  §
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HLA 
A2/DP4
DTH 
Peptide
pre post  
cycle 1
post  
cycle 2
follow up sample pre post pre post
F-1 - 8 A2/DP4 - - 25,600 51,200 -    - -    -
F-2 + 2 A2/DP4 - - 25,600 n.e.  n.e. n.e.  n.e.
F-3 - 15 A2/DP4 - - 51,200 200,000  25.600   (27 m) -   +    (w28) -  +   (w28)
F-4 - 5 DP4 - - 51,200 51,200    6.400   (20 m) -   +    (w12) -  +   (w18)
F-5 n.a. 8 DP4 - - 25,600 51,200 -    - -    - 
F-6 n.a. 20 DP4 - - 25,600 200,000 -   +    (w28) -    - 
F-7 - 4 DP4 - - 200,000  12.800   (11 m) -   +    (w  7) -  +   (w10)
F-8 n.a. 7 DP4 - - 25,600 100,000    1.600   (18 m) -   +    (w10) -    - 
F-9 n.a. 4 A2 - - 200,000   800   (14 m) -   +    (w  7) -  +   (w10)
F-10 + 6 -/- n.a. 6,400 25,600 51,200 -   +    (w10) -  +   (w10)
F-11 - 6 A2/DP4 - - 51,200 100,000 -    -  -    - 
F-12 - 6 DP4 - - 25,600 51,200  12.800   (12 m) -   +    (w19) -  +   (w19)
ZH-1 - 4 DP4 - - 6,400 -    - -    -
ZH-2 - 8 DP4 - - 100,000 200,000  100.000   (  5 m) -   +    (w  7) -    -
ZH-3 - 1 A2 - -  - n.e.  n.e. n.e.  n.e.
DTH, delayed-type hypersensitivity to NY-ESO-1 p157-165/ DP4 peptide; pre, prevaccination; post, postvaccination; m, months; w, study week; 
n.a., not applicable; n.e., not evaluable; 
Values in brackets represent the study week T-cell responses were detectable and antibody persistance in months for follow up samples 
             
Patient
             
ESO 
Tumor
              
No. of 
Vaccines
maximum NY-ESO-1 antibody titer CD8CD4
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